Exactly. Competitive tension is what is now required here. I sincerely hope we’ve got the M&A nous around our board table to generate this and to act accordingly. I am all for the patients and the science, but I’m also all for an investment return/capital appreciation too!
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
-0.003(0.77%) |
Mkt cap ! $475.7M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.0¢ | 32.0¢ | $299.7K | 924.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 204787 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 116111 | 30 |
View Market Depth
| Last trade - 12.24pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |